Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company specializing in the research, development, and commercialization of Diffusing Alpha-emitters Radiation Therapy, known as Alpha DaRT, for treating solid tumors. This innovative technology uses interstitial radioactive sources containing radium-224 to release short-lived alpha-emitting atoms that diffuse within the tumor, delivering a high-energy, short-range radiation dose that targets and destroys cancer cells while sparing surrounding healthy tissue. Alpha DaRT is currently in clinical trials for skin cancer, oral cavity cancer, prostate cancer, pancreatic cancer, breast cancer, and preclinical or pending studies for other indications including lung, liver, and brain cancers. The company operates in the biotechnology sector within healthcare, focusing on tumors with high unmet medical needs, such as those without effective standard treatments. Founded in 2015 and headquartered in Jerusalem, Israel, Alpha Tau Medical Ltd. advances this alpha radiation platform through partnerships with leading medical institutions worldwide to address challenging solid malignancies.